Применение генно-инженерных биологических препаратов для лечения ревматоидного артрита: общая характеристика (лекция)

1. <div><p>Scott D., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010;376:1094-108</p><p>McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. New Engl Med 2012;365:2205-19.</p><p>Feldman M., Maini R.N. Role of cytokines in rheumatoid arthritis: an education in pathophysiology ant therapeutics. Immunology Rev 2008;223:7-19.</p><p>Smolen J.S., Aletaha D., Redlich K. The pathogenesis of rheumatoid arthritis: new insight from old clinical data? Nat Rev Rheumatol 2012;8:235-43.</p><p>Smolen J.S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-71.</p><p>Van Vollenhoven R.F. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531-41.</p><p>Sokka T., Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet 2009;374:430-2.</p><p>Smolen J.S., Aletaha D., Bijsma J.W.J. et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.</p><p>Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.</p><p>Aletaha D., Neogri T., Silman A.J. et al. 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthr Rheum 2010;62:2569-81.</p><p>Felson D.T., Smolen J.S., Wells G. et al. American College of European Rheumatology/League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthr Rheum 2011;63:573-86.</p><p>Насонов Е.Л. Лечение ревматоидного артрита 2012: место метотрексата. Науч-практич ревматол 2012;52(Прил. 1):1 —24.</p><p>Попкова Т.В., Герасимова Е.В., Новикова Д.С., Насонов Е.Л. Метотрексат и риск сердечно-сосудистых осложнений при ревматоидном артрите. Науч-практич ревматол 2012;6:70-9.</p><p>Wasco M.C.M., Dasgupta A., Hubert H. et al. Propensity-adjusted assoviation of methotrexate with overall survival in rheumatoid arthritis. Arthr Rheum 2013;65:334-42.</p><p>Tracey D., Klareskog L., Sasso E.H. et al. Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther 2008;117:244-79.</p><p>Taylor P.C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010;10:308—15.</p><p>Furst D.E., Keystone E.C., Braun J. et al. Update consensus statement on biological agents for the treatment of rheumatic disease, 2011. Ann Rheum Dis 2012;71(Suppl II):i2—i45.</p><p>Atzeni F., Talotta R., Benucci M. et al. Immunogenecity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2012 [Epub. ahead of print].</p><p>Vincent F., Morand E.F., Murphy K. et al. Antidrug antibodies (ADAs) to tumor necrosis factor (TNF)-specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.</p><p>Насонов Е.Л. Место голимумаба в лечении ревматоидного артрита. Науч-практич ревматол 2012;52(Прил. 3):2—10.</p><p>Насонов Е.Л., Амирджанова В.Н. Новые аспекты фармакотерапии ревматоидного артрита: фокус на цертолизумаб. Науч-практич ревматол 2011;1:40-9.</p><p>Насонов Е.Л. Этанерцепт: итоги и перспективы применения при ревматоидном артрите. Науч-практич ревматол 2012;53(Прил. 4):2—21.</p><p>Nam J.L., Wintrop K.L., van Vollenhoven R.F. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systemic literature rewires informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010,69:976—86.</p><p>Woodrick R.S., Ruderman E.M. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol 2011;7:639-52.</p><p>Насонов Е.Л. Применение тоцилизумаба при ревматоидном артрите: новые данные. Науч-практич ревматол 2011;6:46-56.</p><p>Smolen J.S., Schoels M.M., Nishimoto N. et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72:482-92.</p><p>Насонов Е.Л. Применение ритуксимаба при ревматоидном артрите. В кн.: Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. Е.Л. Насонова. М.: ИМА-ПРЕСС, 2011;55—93.</p><p>Buch M.H., Smolen J.S., Betteridge N. et al. Updated consensus statement on the use of Rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20.</p><p>Bukhari M., Abernethy R., Deighton C. et al. BSR and BHPR guidelines on the use of Rituximab in rheumatoid arthritis. Rheumatology 2011;50:2311-3.</p><p>Isaacs J.D., Cohen S.B., Emery P. et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rit-uximab clinical response: a meta-analysis. Ann Rheum Dis 2013;72:329—36.</p><p>Maneiro R.J., Salfado E., Carmona L., Gomez-Reino J.J. Rheumatoid factor as predictor of response to abatacept, ritux-imab and tocilizumab in rheumatoid arthritis: systemic review and meta-analysis. Semin Arthr Rheum 2013 [Epub. ahead of print].</p><p>NICE. Rheumatoid arthritis—drugs for treatment after failure of a TNF inhibitor: final appraisal determination. http://guidance.nice.org.uk/TA/WaveR/61/FAD/FinalAppraisalD etermination/pdf/ (19 July 2010).</p><p>Насонов Е.Л., Каратеев Д.И. Применение блокатора ко-стимуляции Т-лимфоцитов абатацепта при ревматоидном артрите. Науч-практич ревматол 2010;4(Прил. 2):9—26.</p></div><br />